The Library
An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD) : the UK protocol
Tools
Tools
Tools
UK GARFIELD Investigators, GARFIELD Steering Committee (Including: Apenteng, Patricia N., Murray, Ellen T., Holder, Roger L., Hobbs, Richard F. D. and Fitzmaurice, David A.). (2013) An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD) : the UK protocol. BMC Cardiovascular Disorders, 13 . 31. doi:https://doi.org/10.1186/1471-2261-13-31
|
PDF
WRAP-An-international-patients-atrial-fibrillation-stroke-GARFIELD-UK-2020.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (356Kb) | Preview |
Official URL: https://doi.org/10.1186/1471-2261-13-31
Abstract
Background
Atrial fibrillation (AF) is an independent risk factor for stroke and a significant predictor of mortality. Evidence-based guidelines for stroke prevention in AF recommend antithrombotic therapy corresponding to the risk of stroke. In practice, many patients with AF do not receive the appropriate antithrombotic therapy and are left either unprotected or inadequately protected against stroke. The purpose of the Global Anticoagulant Registry in the FIELD (GARFIELD) is to determine the real-life management and outcomes of patients newly diagnosed with non-valvular AF.
Methods/design
GARFIELD is an observational, international registry of newly diagnosed AF patients with at least one additional investigator-defined risk factor for stroke. The aim is to enrol 55,000 patients at more than 1000 centres in 50 countries worldwide. Enrolment will take place in five independent, sequential, prospective cohorts; the first cohort includes a retrospective validation cohort. Each cohort will be followed up for 2 years. The UK stands to be a significant contributor to GARFIELD, aiming to enrol 4,582 patients, and reflecting the care environment in which patients with AF are managed. The UK protocol will also focus on better understanding the validity of the two main stroke risk scores (CHADS2 and CHA2DS2VASC) and the HAS-BLED bleeding risk score, in the context of a diverse patient population.
Discussion
The GARFIELD registry will describe how therapeutic strategies, patient care, and clinical outcomes evolve over time. This study will provide UK-specific comprehensive data that will allow a range of evaluations both at a national level and in relation to global data and contribute to a better understanding of AF management in the UK.
| Item Type: | Journal Article | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
|||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
|||||||||
| Library of Congress Subject Headings (LCSH): | Anticoagulants (Medicine) , Atrial fibrillation , Cerebrovascular disease , Cerebrovascular disease -- Patients , Vitamin K | |||||||||
| Journal or Publication Title: | BMC Cardiovascular Disorders | |||||||||
| Publisher: | BioMed Central Ltd. | |||||||||
| ISSN: | 1471-2261 | |||||||||
| Official Date: | 23 April 2013 | |||||||||
| Dates: |
|
|||||||||
| Date of first compliant deposit: | 8 October 2020 | |||||||||
| Volume: | 13 | |||||||||
| Article Number: | 31 | |||||||||
| DOI: | https://doi.org/10.1186/1471-2261-13-31 | |||||||||
| Status: | Peer Reviewed | |||||||||
| Publication Status: | Published | |||||||||
| Access rights to Published version: | Open Access | |||||||||
| RIOXX Funder/Project Grant: |
|
|||||||||
| Open Access Version: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
